Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2015

Restricted access

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin’s Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.

  • 1.

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma: the Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:39093918.

    • Search Google Scholar
    • Export Citation
  • 2.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:529.

  • 3.

    Hallek M, Cheson BD, Catovsky D. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:54465456.

    • Search Google Scholar
    • Export Citation
  • 4.

    Tsimberidou AM, Wen S, O’Brien S. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center. J Clin Oncol 2007;25:46484656.

    • Search Google Scholar
    • Export Citation
  • 5.

    Rawstron AC. Monoclonal B-cell lymphocytosis. Hematology Am Soc Hematol Educ Program 2009:430439.

  • 6.

    Rawstron AC, Bennett FL, O’Connor SJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575583.

  • 7.

    Baliakas P, Iskas M, Gardiner A. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data. Am J Hematol 2014;89:249255.

    • Search Google Scholar
    • Export Citation
  • 8.

    Woyach JA, Ruppert AS, Lozanski G. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: a single-center experience of 267 patients [abstract]. J Clin Oncol 2014;32(15_suppl):Abstract 7010.

    • Search Google Scholar
    • Export Citation
  • 9.

    Thompson PA, Wierda WG, Ferrajoli A. Complex karyotype, rather than del(17p), is associated with inferior outcomes in relapsed or refractory CLL patients treated with ibrutinib-based regimens [abstract]. Blood 2014;124:Abstract 22.

    • Search Google Scholar
    • Export Citation
  • 10.

    Dicker F, Schnittger S, Haferlach T. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006;108:31523160.

    • Search Google Scholar
    • Export Citation
  • 11.

    Put N, Konings P, Rack K. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009;48:843853.

    • Search Google Scholar
    • Export Citation
  • 12.

    Struski S, Gervais C, Helias C. Stimulation of B-cell lymphoproliferations with CpG-oligonucleotide DSP30 plus IL-2 is more effective than with TPA to detect clonal abnormalities. Leukemia 2009;23:617619.

    • Search Google Scholar
    • Export Citation
  • 13.

    Heerema NA, Byrd JC, Dal Cin PS. Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) study. Cancer Genet Cytogenet 2010;203:134140.

    • Search Google Scholar
    • Export Citation
  • 14.

    Crespo M, Bosch F, Villamor N. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:17641775.

    • Search Google Scholar
    • Export Citation
  • 15.

    Damle RN, Wasil T, Fais F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:18401847.

    • Search Google Scholar
    • Export Citation
  • 16.

    Del Poeta G, Maurillo L, Venditti A. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001;98:26332639.

  • 17.

    Dohner H, Stilgenbauer S, Benner A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:19101916.

  • 18.

    Hallek M, Langenmayer I, Nerl C. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:17321737.

    • Search Google Scholar
    • Export Citation
  • 19.

    Hallek M, Wanders L, Ostwald M. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439447.

    • Search Google Scholar
    • Export Citation
  • 20.

    Hamblin TJ, Davis Z, Gardiner A. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:18481854.

    • Search Google Scholar
    • Export Citation
  • 21.

    Hamblin TJ, Orchard JA, Ibbotson RE. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:10231029.

    • Search Google Scholar
    • Export Citation
  • 22.

    Ibrahim S, Keating M, Do KA. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181186.

    • Search Google Scholar
    • Export Citation
  • 23.

    Orchard JA, Ibbotson RE, Davis Z. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004;363:105111.

  • 24.

    Rassenti LZ, Huynh L, Toy TL. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351:893901.

    • Search Google Scholar
    • Export Citation
  • 25.

    Wiestner A, Rosenwald A, Barry TS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:49444951.

    • Search Google Scholar
    • Export Citation
  • 26.

    Bulian P, Shanafelt TD, Fegan C. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. J Clin Oncol 2014;32:897904.

    • Search Google Scholar
    • Export Citation
  • 27.

    Tobin G, Thunberg U, Johnson A. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002;99:22622264.

    • Search Google Scholar
    • Export Citation
  • 28.

    Krober A, Bloehdorn J, Hafner S. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006;24:969975.

    • Search Google Scholar
    • Export Citation
  • 29.

    Krober A, Seiler T, Benner A. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:14101416.

    • Search Google Scholar
    • Export Citation
  • 30.

    Oscier D, Wade R, Davis Z. Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica 2010;95:17051712.

    • Search Google Scholar
    • Export Citation
  • 31.

    Oscier DG, Gardiner AC, Mould SJ. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:11771184.

    • Search Google Scholar
    • Export Citation
  • 32.

    Gentile M, Mauro FR, Calabrese E. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005;130:549557.

    • Search Google Scholar
    • Export Citation
  • 33.

    Del Principe MI, Del Poeta G, Buccisano F. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006;108:853861.

    • Search Google Scholar
    • Export Citation
  • 34.

    Rassenti LZ, Jain S, Keating MJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008;112:19231930.

    • Search Google Scholar
    • Export Citation
  • 35.

    Corcoran M, Parker A, Orchard J. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005;90:10781088.

    • Search Google Scholar
    • Export Citation
  • 36.

    Claus R, Lucas DM, Stilgenbauer S. Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012;30:24832491.

    • Search Google Scholar
    • Export Citation
  • 37.

    Claus R, Lucas DM, Ruppert AS. Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood 2014;124:4248.

    • Search Google Scholar
    • Export Citation
  • 38.

    Tam CS, O’Brien S, Wierda W. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975980.

    • Search Google Scholar
    • Export Citation
  • 39.

    Tsimberidou AM, Tam C, Wierda W. Beta-2 microglobulin (B2M) is an independent prognostic factor for clinical outcomes in patients with CLL treated with frontline fludarabine, cyclophosphamide, and rituximab (FCR) regardless of age, creatinine clearance (CrCl) [abstract]. J Clin Oncol 2007;25:Abstract 7034.

    • Search Google Scholar
    • Export Citation
  • 40.

    Wierda WG, O’Brien S, Wang X. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol 2009;27:16371643.

    • Search Google Scholar
    • Export Citation
  • 41.

    Wierda WG, O’Brien S, Wang X. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007;109:46794685.

    • Search Google Scholar
    • Export Citation
  • 42.

    Shanafelt TD, Jenkins G, Call TG. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009;115:363372.

    • Search Google Scholar
    • Export Citation
  • 43.

    Molica S, Mauro FR, Callea V. The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. Haematologica 2010;95:464469.

    • Search Google Scholar
    • Export Citation
  • 44.

    Neilson JR, Auer R, White D. Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival. Leukemia 1997;11:19291932.

    • Search Google Scholar
    • Export Citation
  • 45.

    Austen B, Skowronska A, Baker C. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:54485457.

    • Search Google Scholar
    • Export Citation
  • 46.

    Tsimberidou AM, Tam C, Abruzzo LV. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer 2009;115:373380.

    • Search Google Scholar
    • Export Citation
  • 47.

    Hallek M, Fischer K, Fingerle-Rowson G. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:11641174.

    • Search Google Scholar
    • Export Citation
  • 48.

    Catovsky D, Richards S, Matutes E. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230239.

    • Search Google Scholar
    • Export Citation
  • 49.

    Stilgenbauer S, Sander S, Bullinger L. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:12421245.

    • Search Google Scholar
    • Export Citation
  • 50.

    Wierda WG, O’Brien S, Wang X. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol 2011;29:40884095.

    • Search Google Scholar
    • Export Citation
  • 51.

    Pflug N, Bahlo J, Shanafelt TD. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood 2014;124:4962.

    • Search Google Scholar
    • Export Citation
  • 52.

    Zenz T, Eichhorst B, Busch R. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 2010;28:44734479.

  • 53.

    Stilgenbauer S, Schnaiter A, Paschka P. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123:32473254.

    • Search Google Scholar
    • Export Citation
  • 54.

    Gonzalez D, Martinez P, Wade R. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 2011;29:22232229.

    • Search Google Scholar
    • Export Citation
  • 55.

    Rossi D, Cerri M, Deambrogi C. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15:9951004.

    • Search Google Scholar
    • Export Citation
  • 56.

    Woyach JA, Ruppert AS, Heerema NA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol 2011;29:13491355.

    • Search Google Scholar
    • Export Citation
  • 57.

    Fabbri G, Rasi S, Rossi D. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011;208:13891401.

    • Search Google Scholar
    • Export Citation
  • 58.

    Puente XS, Pinyol M, Quesada V. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011;475:101105.

    • Search Google Scholar
    • Export Citation
  • 59.

    Wang L, Lawrence MS, Wan Y. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011;365:24972506.

  • 60.

    Quesada V, Conde L, Villamor N. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2012;44:4752.

    • Search Google Scholar
    • Export Citation
  • 61.

    Rossi D, Fangazio M, Rasi S. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012;119:28542862.

    • Search Google Scholar
    • Export Citation
  • 62.

    Messina M, Del Giudice I, Khiabanian H. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014;123:23782388.

    • Search Google Scholar
    • Export Citation
  • 63.

    Rossi D, Rasi S, Spina V. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 2013;121:14031412.

    • Search Google Scholar
    • Export Citation
  • 64.

    Oscier DG, Rose-Zerilli MJ, Winkelmann N. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013;121:468475.

    • Search Google Scholar
    • Export Citation
  • 65.

    Schnaiter A, Paschka P, Rossi M. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013;122:12661270.

    • Search Google Scholar
    • Export Citation
  • 66.

    Rossi D, Rasi S, Spina V. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol 2012;158:426429.

    • Search Google Scholar
    • Export Citation
  • 67.

    Villamor N, Conde L, Martinez-Trillos A. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2013;27:11001106.

    • Search Google Scholar
    • Export Citation
  • 68.

    Conte MJ, Bowen DA, Wiseman GA. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma 2014;55:20792084.

    • Search Google Scholar
    • Export Citation
  • 69.

    Falchi L, Keating MJ, Marom EM. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood 2014;123:27832790.

    • Search Google Scholar
    • Export Citation
  • 70.

    Rai KR, Sawitsky A, Cronkite EP. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219234.

  • 71.

    Binet J, Auquier A, Dighiero G. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198206.

    • Search Google Scholar
    • Export Citation
  • 72.

    Cheson BD, Bennett JM, Grever M. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:49904997.

    • Search Google Scholar
    • Export Citation
  • 73.

    Cheson BD, Byrd JC, Rai KR. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol 2012;30:28202822.

    • Search Google Scholar
    • Export Citation
  • 74.

    Chanan-Khan A, Miller KC, Lawrence D. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011;117:21272135.

    • Search Google Scholar
    • Export Citation
  • 75.

    Byrd JC, Furman RR, Coutre SE. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:3242.

  • 76.

    Furman RR, Sharman JP, Coutre SE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:9971007.

  • 77.

    Woyach JA, Smucker K, Smith LL. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123:18101817.

    • Search Google Scholar
    • Export Citation
  • 78.

    Kovacs G, Boettcher S, Bahlo J. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL Study Group (GCLLSG) [abstract]. Blood 2014;124:Abstract 23.

    • Search Google Scholar
    • Export Citation
  • 79.

    Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood 2013;121:15011509.

    • Search Google Scholar
    • Export Citation
  • 80.

    Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013;2013:553560.

  • 81.

    Goede V, Fischer K, Busch R. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:11011111.

  • 82.

    Flynn JM, Byrd JC, Kipps TJ. Obinutuzumab (GA101) 1,000 mg versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial [abstract]. J Clin Oncol 2014;32(Suppl 15):Abstract 7083.

    • Search Google Scholar
    • Export Citation
  • 83.

    Robak T, Janssens A, Govindbabu K. Ofatumumab + chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911) [abstract]. Blood 2013;122:Abstract 528.

    • Search Google Scholar
    • Export Citation
  • 84.

    O’Brien S, Furman RR, Coutre SE. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:4858.

    • Search Google Scholar
    • Export Citation
  • 85.

    O’Brien SM, Furman RR, Coutre SE. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease [abstract]. J Clin Oncol 2014;32(15_suppl):Abstract 7014.

    • Search Google Scholar
    • Export Citation
  • 86.

    Wiestner A, Farooqui M, Valdez J. Single agent ibrutinib (PCI-32765) is highly effective in chronic lymphocytic leukaemia patients with 17p deletion [abstract]. Hematol Oncol 2013;31(Suppl 1):98 (Abstract 008).

    • Search Google Scholar
    • Export Citation
  • 87.

    Zelenetz AD, Lamanna N, Kipps TJ. A phase 2 study of idelalisib monotherapy in previously untreated patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood 2014;124:Abstract 1986.

    • Search Google Scholar
    • Export Citation
  • 88.

    O’Brien S, Lamanna N, Kipps TJ. Update on a phase 2 study of idelalisib in combination with rituximab in treatment-naïve patients ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. Blood 2014;124:Abstract 1994.

    • Search Google Scholar
    • Export Citation
  • 89.

    Brown JR, Byrd JC, Coutre SE. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:33903397.

    • Search Google Scholar
    • Export Citation
  • 90.

    Advani RH, Buggy JJ, Sharman JP. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:8894.

    • Search Google Scholar
    • Export Citation
  • 91.

    Byrd JC, Brown JR, O’Brien S. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213223.

  • 92.

    Brown JR, Hillmen P, O’Brien S. Updated efficacy including genetic and clinical subgroup analysis and overall safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma [abstract]. Blood 2014;124:Abstract 3331.

    • Search Google Scholar
    • Export Citation
  • 93.

    O’Brien S, Jones JA, Coutre S. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial [abstract]. Blood 2014;124:Abstract 327.

    • Search Google Scholar
    • Export Citation
  • 94.

    Sharman JP, Coutre SE, Furman RR. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]. Blood 2014;124:Abstract 330.

    • Search Google Scholar
    • Export Citation
  • 95.

    Sharman JP, Coutre SE, Furman RR. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: results from a phase 3, randomized, double-blind, placebo-controlled trial [abstract]. J Clin Oncol 2014;32(15_suppl):Abstract 7011.

    • Search Google Scholar
    • Export Citation
  • 96.

    Wierda WG, Kipps TJ, Mayer J. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:17491755.

    • Search Google Scholar
    • Export Citation
  • 97.

    Wierda WG, Kipps TJ, Mayer J. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia [abstract]. Blood 2010;116:Abstract 921.

    • Search Google Scholar
    • Export Citation
  • 98.

    Wierda WG, Padmanabhan S, Chan GW. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood 2011;118:51265129.

    • Search Google Scholar
    • Export Citation
  • 99.

    Cartron G, de Guibert S, Dilhuydy MS. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014;124:21962202.

    • Search Google Scholar
    • Export Citation
  • 100.

    Goede V, Engelke A, Fischer K. Salvage therapy with obinutuzumab (GA101) plus chlorambucil (Clb) after treatment failure of Clb alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities: results of the CLL11 study [abstract]. Blood 2014;124:Abstract 3327.

    • Search Google Scholar
    • Export Citation
  • 101.

    Gribben JG, Zahrieh D, Stephans K. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:43894396.

    • Search Google Scholar
    • Export Citation
  • 102.

    Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy 2002;4:217221.

    • Search Google Scholar
    • Export Citation
  • 103.

    Sorror ML, Storer BE, Sandmaier BM. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:49124920.

    • Search Google Scholar
    • Export Citation
  • 104.

    Khouri IF, Saliba RM, Admirand J. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 2007;137:355363.

    • Search Google Scholar
    • Export Citation
  • 105.

    Moreno C, Villamor N, Colomer D. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005;23:34333438.

    • Search Google Scholar
    • Export Citation
  • 106.

    Schetelig J, van Biezen A, Brand R. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol 2008;26:50945100.

    • Search Google Scholar
    • Export Citation
  • 107.

    Dreger P, Dohner H, Ritgen M. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010;116:24382447.

    • Search Google Scholar
    • Export Citation
  • 108.

    Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009;115:28242836.

  • 109.

    National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/html/clyl.html. Accessed August 2012.

    • Search Google Scholar
    • Export Citation
  • 110.

    Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:171178.

  • 111.

    Eichhorst BF, Busch R, Stilgenbauer S. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:33823391.

    • Search Google Scholar
    • Export Citation
  • 112.

    Thurmes P, Call T, Slager S. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008;49:4956.

    • Search Google Scholar
    • Export Citation
  • 113.

    Goede V, Cramer P, Busch R. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica 2014;99:10951100.

    • Search Google Scholar
    • Export Citation
  • 114.

    Satram-Hoang S, Reyes C, Hoang KQ. Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database. Ann Hematol 2014;93:13351344.

    • Search Google Scholar
    • Export Citation
  • 115.

    Salvi F, Miller MD, Grilli A. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008;56:19261931.

    • Search Google Scholar
    • Export Citation
  • 116.

    Hillmen P, Gribben JG, Follows GA. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study. J Clin Oncol 2014;32:12361241.

    • Search Google Scholar
    • Export Citation
  • 117.

    Foa R, Giudice ID, Cuneo A. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014;89:480486.

    • Search Google Scholar
    • Export Citation
  • 118.

    Fischer K, Cramer P, Busch R. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:32093216.

    • Search Google Scholar
    • Export Citation
  • 119.

    Eichhorst B, Fink AM, Busch R. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study) [abstract]. Blood 2014;124:Abstract 19.

    • Search Google Scholar
    • Export Citation
  • 120.

    Gopal AK, Kahl BS, de Vos S. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370:10081018.

    • Search Google Scholar
    • Export Citation
  • 121.

    Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005;103:221228.

  • 122.

    Tsimberidou AM, O’Brien S, Kantarjian HM. Hodgkin transformation of chronic lymphocytic leukemia: the M D Anderson Cancer Center experience. Cancer 2006;107:12941302.

    • Search Google Scholar
    • Export Citation
  • 123.

    Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol 2009;27:110.

  • 124.

    Chigrinova E, Rinaldi A, Kwee I. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood 2013;122:26732682.

    • Search Google Scholar
    • Export Citation
  • 125.

    Fabbri G, Khiabanian H, Holmes AB. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013;210:22732288.

    • Search Google Scholar
    • Export Citation
  • 126.

    Tsimberidou AM, O’Brien S, Khouri I. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006;24:23432351.

    • Search Google Scholar
    • Export Citation
  • 127.

    Tadmor T, Shvidel L, Goldschmidt N. Hodgkin’s variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study group. Anticancer Res 2014;34:785790.

    • Search Google Scholar
    • Export Citation
  • 128.

    Tsimberidou AM, Kantarjian HM, Cortes J. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:17111720.

    • Search Google Scholar
    • Export Citation
  • 129.

    Tsimberidou AM, Wierda WG, Plunkett W. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008;26:196203.

    • Search Google Scholar
    • Export Citation
  • 130.

    Tsimberidou AM, Wierda WG, Wen S. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013;13:568574.

    • Search Google Scholar
    • Export Citation
  • 131.

    Cwynarski K, van Biezen A, de Wreede L. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter’s syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012;30:22112217.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 474 353 34
PDF Downloads 139 116 21
EPUB Downloads 0 0 0